News
SNBIF
9.40
NaN%
--
SanBio Issues New Employee Stock Options to Support Long-Term Growth
TipRanks · 01/09 07:01
SanBio Co. Records Significant Non-Operating Expenses and Deferred Income Taxes
TipRanks · 12/15/2025 07:01
SanBio Reports Continued Financial Losses Amid Operational Challenges
TipRanks · 12/15/2025 07:01
SanBio initiated with a Neutral at UBS
TipRanks · 12/14/2025 14:10
UBS Initiates a Hold Rating on SanBio Co (SNBIF)
TipRanks · 12/14/2025 13:55
SanBio Gains Approval for AKUUGO Marketing Changes
TipRanks · 12/09/2025 06:54
SanBio Co. Announces International Offering to Fund Key Clinical Trials
TipRanks · 11/06/2025 14:52
SanBio Co. Announces International Share Offering to Fund Regenerative Medicine Expansion
TipRanks · 11/06/2025 08:27
SanBio’s AKUUGO Gains Approval for Launch, Eyes Global Expansion
TipRanks · 10/16/2025 11:52
SanBio Co. Reports Losses Amid R&D Investments
Barchart · 10/04/2025 22:54
SanBio Awaits Regulatory Decision on AKUUGO Suspension
TipRanks · 10/02/2025 06:52
SanBio Co (SNBIF) Gets a Sell from Jefferies
TipRanks · 09/26/2025 12:45
Weekly Report: what happened at SNBIF last week (0908-0912)?
Weekly Report · 09/15/2025 11:48
SanBio Revises Earnings Forecast, Projects Greater Loss
TipRanks · 09/12/2025 07:05
SanBio Co. Reports Financial Adjustments Amid Currency Fluctuations
TipRanks · 09/12/2025 07:04
SanBio Co. Reports Increased Losses in First Half of 2025
TipRanks · 09/12/2025 07:04
Weekly Report: what happened at SNBIF last week (0901-0905)?
Weekly Report · 09/08/2025 11:50
Weekly Report: what happened at SNBIF last week (0825-0829)?
Weekly Report · 09/01/2025 11:45
Weekly Report: what happened at SNBIF last week (0818-0822)?
Weekly Report · 08/25/2025 11:58
More
Webull provides a variety of real-time SNBIF stock news. You can receive the latest news about Sanbio Co Ltd through multiple platforms. This information may help you make smarter investment decisions.
About SNBIF
SanBio Co Ltd is engaged in the regenerative cell business using allogeneic stem cells. The Company has the research and development base in the United States and conducts research, development, manufacture and sale of regenerative cell medicines in Japan. The Company aims to sell therapeutic agents for diseases with high unmet medical needs, mainly in diseases of the central nervous system. It is involved in the manufacture, development, non-clinical studies, clinical trials of technologies introduced from research institutes such as universities. The Company has five regenerative cell drugs, including the main product candidate SB623 (nerve regenerative cells), SB618 (function-enhancing type & Mesenchymal stem cells), SB308 (muscle stem cells), MSC1 (mesenchymal stem cells), and MSC2 (mesenchymal stem cells).